Please login to the form below

Not currently logged in
Email:
Password:

orphan diseases

This page shows the latest orphan diseases news and features for those working in and with pharma, biotech and healthcare.

Malthus’ orphans

Malthus’ orphans

Shire. The attractiveness of rare diseases, orphan drugs and other ‘ultra niche’strategies is their high relative profitability; governments tolerate high cost per patient because the patients are few and often ... By and large, rare diseases and

Latest news

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Five of the 12 drugs  we identified are first-in-class  and

  • Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

    Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report. ... That assertion ties in with its new report on worldwide prescription drug sales, which says that drugs for orphan diseases will outperform the overall pharma market,

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    smaller $101m collaboration with Vividion Therapeutics that also covers cancer and inflammatory diseases targets. ... Our collaboration leverages each company’s core expertise in protein homeostasis and protein clearance to target proteins that are the

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life Sciences - all have an interest in DMD as well as other rare and orphan diseases that can have difficulties ... These delays are worsened for diseases as there

  • Lucid picks up rare disease and orphan drugs trophy at PMEA 2017 Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

    Judges praised the AbbVie project for its impressive reach. Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted ... Narrowly missing first place, but still achieving a highly

More from news
Approximately 3 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    During 2016, special approval procedures like conditional and accelerated approval pathways were issued for seven of the new approvals in the EU, the majority in oncology and for orphan diseases. ... We expect the strong overall trend for more orphan

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Rare diseases: meeting the challenge. Problems with regulating orphan drugs. The European Medicines Agency estimates that 30 million people living in the European Union suffer from a rare disease. ... Numbers game. The number of orphan drugs actually

  • Deal Watch February 2017 Deal Watch February 2017

    IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies for metastatic disease and also has Fast Track status and orphan designation ... The amendment gives Vifor the rights to

  • A rare talent A rare talent

    A rare challenge. That knowledge is currently focused on bringing new treatments to market for rare diseases and working to ensure the environment for orphan drugs is fit-for-purpose, twin ... At the forefront of his mind is the position of access to

  • Mastering the rare disease challenge Mastering the rare disease challenge

    Mastering the rare disease challenge. Identifying expertise and customising communication in orphan drug marketing. ... Orphan drugs are few and far between. Long awaited by patients and physicians, it should be an easy job to market them.

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics